Branch Retinal Vein Occlusion
Conditions
Interventions
Test group:Faricizumab injected monthly until the effusion subsided and treated as needed
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years, regardless of sex; 2. Macular edema secondary to branch retinal vein occlusion (BRVO), confirmed by the investigator based on clinical and imaging findings; 3. Treatment-naïve: the study eye has not received any prior treatment for macular edema; 4. Central subfield thickness (CST) meets the predefined threshold: measured by swept-source OCT, CST >=320 µm; 5. Best-corrected visual acuity (BCVA) within the eligible range: ETDRS letter score between 73 and 19 (equivalent to Snellen 20/40 to 20/400); 6. Availability of clear ocular imaging, including OCT/OCTA, fundus photography, and reliable visual acuity measurements; 7. Only one study eye will be included: if both eyes are eligible, the eye with worse visual acuity will be selected; 8. Ability to comply with the study protocol, complete follow-up visits, and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Macular edema in the study eye not caused by BRVO (e.g., diabetic retinopathy, CRVO, etc.); 2. Structural abnormalities in the study eye that may affect retinal thickness or visual acuity assessment, including vitreous hemorrhage, tractional retinal detachment, moderate or severe vitreous opacity, active intraocular inflammation, history of ocular trauma, significant epiretinal membrane, or macular hole; 3. Prior treatments in the study eye that may affect macular structure, including anti-VEGF therapy, intravitreal corticosteroid injection, laser photocoagulation, or vitrectomy; 4. Coexisting ocular diseases in the study eye that may severely affect visual function, such as uveitis, advanced glaucoma (MD < -20 dB), optic atrophy, or ischemic optic neuropathy; 5. Inability to obtain high-quality fundus images in the study eye, due to factors such as abnormal pupil or severe media opacity; 6. History of major cardiovascular or cerebrovascular events within the past 6 months, including myocardial infarction, stroke, or transient ischemic attack; 7. Uncontrolled hypertension (systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg); 8. Bleeding tendency or current use of anticoagulants that cannot be adjusted; 9. Pregnancy or lactation, or plans for pregnancy in the near future; 10. Known hypersensitivity to the study drug components (e.g., Faricimab or its excipients); 11. Inability to comply with scheduled follow-up or study procedures; 12. Participation in another clinical trial that may affect the evaluation of this study within the past 30 days; 13. Any other serious condition judged by the investigator that may increase risk or interfere with study outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best Corrected Visual Acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Central Macular Thickness (CMT);Total Number of Injections;Retinal Vascular Density (RVD); | — |
Countries
China
Contacts
Public ContactYanping Zhou
Zhongshan Hospital, Fudan University
Outcome results
None listed